Related Experiment Video

Updated: Aug 29, 2026

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery
10:03

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery

Published on: November 5, 2019

Development of new vaccines against meningococcal disease

Michael Bröker1

  • 1Chiron Vaccines, Chiron Behring GmbH & Co. KG, Post Box 1630, 35006 Marburg, Germany. Michael_Broeker@Chiron.com

Arzneimittel-Forschung
|January 22, 2004
PubMed

Insights

Meningococcal vaccines target five Neisseria meningitidis groups. Current vaccines have limitations, prompting research into new conjugate vaccines, especially for serogroup B, a significant invasive disease cause.

Area of Science:

  • Microbiology
  • Immunology
  • Vaccinology

Background:

  • Meningococcal diseases pose a significant public health threat globally.
  • Neisseria meningitidis serogroups A, B, C, Y, and W-135 cause the majority of invasive meningococcal disease.
  • Conventional polysaccharide vaccines offer limited efficacy in young children and short-lived immunity.

Purpose of the Study:

  • To review current and emerging vaccine development strategies for pathogenic Neisseria meningitidis.
  • To highlight the limitations of existing meningococcal vaccines.
  • To address the unmet need for a serogroup B vaccine.

Main Methods:

  • Review of existing literature on meningococcal vaccines.
  • Analysis of polysaccharide and conjugate vaccine technologies.
  • Discussion of novel vaccine approaches.

Main Results:

  • Plain polysaccharide vaccines (MPSV) against serogroups A, C, Y, and W-135 have been used for decades.
  • Conjugate vaccines for meningococcal group C (MenCC) demonstrate improved immunogenicity and efficacy.
  • No licensed vaccine currently exists for Neisseria meningitidis serogroup B, a leading cause of invasive disease.

Conclusions:

  • Advances in conjugate vaccine technology have improved protection against certain meningococcal serogroups.
  • Development of an effective serogroup B meningococcal vaccine remains a critical public health priority.
  • Continued research into novel vaccine platforms is essential to combat meningococcal disease globally.

More Related Videos

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens13:47

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens

Published on: May 19, 2020

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice08:52

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice

Published on: February 22, 2019

Related Concept Videos

Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
Bacterial Meningitis II: Pathophysiology01:26

Bacterial Meningitis II: Pathophysiology

Bacterial meningitis typically begins when pathogens such as Neisseria meningitidis and Streptococcus pneumoniae colonize the nasopharynx and invade the bloodstream. This process is facilitated by bacterial virulence factors, such as polysaccharide capsules, which resist phagocytosis and complement-mediated killing. Less commonly, bacteria reach the central nervous system via contiguous spread from infections like otitis media or sinusitis, through congenital or acquired dural defects, or...
Vaccine Production01:23

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
Vaccinations01:51

Vaccinations

Overview
Bacterial Meningitis I: Introduction01:22

Bacterial Meningitis I: Introduction

Bacterial meningitis is a severe, life-threatening inflammation of the meninges, particularly the pia mater and arachnoid mater, affecting the subarachnoid space, ventricles, and cerebrospinal fluid (CSF). If untreated, it can lead to significant neurological complications or death.Causative AgentsCommon pathogens vary with age and immune status. In adults, major organisms include Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae. Streptococcus agalactiae (group B...
Vaccines01:21

Vaccines

Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the type of...